Compare HCA Health Inc (HCA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs State Street SPDR S&P Biotech ETF — how do they compare? HCA Health Inc trades at $373.29 (market cap $82.17B), while State Street SPDR S&P Biotech ETF trades at $154.37. The key difference: HCA Health Inc pays a 0.84% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, HCA Health Inc nearer its low. Which is the better fit depends on your goals.
| HCA | XBI | |
|---|---|---|
Market Cap | $82.17B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $545.13 | $164.28 |
52-Week Low | $334.32 | $85.16 |
Enterprise Value | $131.08B | — |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $373.09, up 0.51% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 preliminary revenue above expectations but cut full-year profit guidance, causing recent stock pressure. Analyst consensus remains bullish with a $469.40 price target, though multiple law firms are investigating potential securities law violations following the guidance revision.
Investment outlook balances strong operational performance against near-term headwinds. The stock offers value with a 12.76 P/E ratio and consistent earnings beats, but faces risks from rising expenses, payer mix challenges, and ongoing legal investigations. Institutional sentiment remains positive despite technical weakness and recent guidance concerns.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
